Short Interest in Sysmex Co. (OTCMKTS:SSMXY) Declines By 97.9%

Sysmex Co. (OTCMKTS:SSMXY - Get Free Report) was the target of a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 600 shares, a decrease of 97.9% from the May 15th total of 28,200 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily volume of 158,100 shares, the days-to-cover ratio is presently 0.0 days.

Sysmex Price Performance

Shares of Sysmex stock traded down $0.22 during mid-day trading on Friday, reaching $17.24. 43,044 shares of the stock were exchanged, compared to its average volume of 71,473. The firm has a 50-day simple moving average of $17.76 and a 200 day simple moving average of $18.44. Sysmex has a fifty-two week low of $14.38 and a fifty-two week high of $22.00. The company has a market cap of $10.85 billion, a price-to-earnings ratio of 30.79 and a beta of 1.14. The company has a current ratio of 3.19, a quick ratio of 2.42 and a debt-to-equity ratio of 0.11.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.16 by ($0.04). The firm had revenue of $958.89 million during the quarter, compared to analyst estimates of $991.22 million. On average, sell-side analysts predict that Sysmex will post 0.57 EPS for the current fiscal year.

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.